Trial reportGenetic testing and molecular biomarkers2013
Association of -2518A>G promoter polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene with type 2 diabetes and coronary artery disease.
Trial report in Genetic testing and molecular biomarkers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 14 citations in OpenAlex.
- Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation ofExperimental and therapeutic medicine · 2021Article
- Monocyte chemoattractant protein-1 polymorphism interaction with spirulina immunomodulatory effects in healthy Korean elderly: A 16 week, double-blind randomized clinical trial.Nutrition research and practice · 2017Article
- The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis.International urology and nephrology · 2015Article
- Association of monocyte chemoattractant protein-1-2518A/G polymorphism and risk of coronary artery disease among the Chinese population: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInflammatory markers play an important role in the development of diseases related to metabolic syndrome, such as type 2 diabetes (T2D) and coronary artery disease (CAD). The present study evaluates the association of -2518A>G polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene with T2D and CAD.
resultsThe frequency of the G allele is greater in CAD cases (35%) as compared to T2D (24.6%) and controls (31%), while the frequency of the A allele is higher in T2D cases (75.4%) as compared to CAD cases (65%) and controls (69%). The analysis has revealed that in comparison to T2D cases, the G allele increases the risk of CAD by 1.9-fold (p=0.008; odds ratio [OR]=1.9, 1.18-3.06 at 95% confidence interval [CI]) but in comparison to controls the G-allele provided protection against T2D (p=0.011; OR=0.55, 0.35-0.87 at 95% CI), both under the dominant model (AG+GG vs. AA).
conclusionResults of the present study suggests that G-allele of MCP-1 -2518A>G polymorphism is associated with reduced risk of T2D and increased risk of CAD in the population of Punjab. The results indicate that there is a difference in the association of risk alleles with phenotypes of metabolic syndrome. Body mass index and waist circumference are important risk factors for T2D in the population of Punjab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.